Cyclosporine Eye Drops (Restasis)
Phase 2Small molecule
Cyclosporine Eye Drops (Restasis) is one of 6 small molecule programs targeting Epiphora. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Epiphora
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Botox
RRevance Therapeutics, Inc.
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Cyclosporine Eye Drops (Restasis)
MM.D. Anderson Cancer Center
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MM.D. Anderson Cancer Center